Research Team

Michael J. Higgins

Managing Director, Senior Biopharmaceuticals Equity Research

Mr. Higgins has 15 years of experience as a biopharmaceuticals analyst. His current focus is on therapeutic companies, including pain/addiction, anti-infectives, neurological and drug delivery. Prior to joining Ladenburg Thalmann, he was a Managing Director, Senior Research Analyst at ROTH Capital Partners as well as Rodman & Renshaw Capital LLC. Mr. Higgins began his career in equity research at Dafna Capital in Beverly Hills, CA where he focused on drug launches of biopharmaceutical companies, which followed ten years in pharmaceutical marketing at Procter & Gamble Pharmaceuticals. Mr. Higgins earned his Bachelor of Science in Finance from the University of Wisconsin-Stevens Point and his MBA with a focus on Finance and Investment Analysis from Marquette University.

Healthcare & Life Sciences

Matthew L. Kaplan

Matthew L. Kaplan

Managing Director, Head of Healthcare Equity Research

Jeffrey S. Cohen

Jeffrey S. Cohen

Managing Director, Equity Research

Wangzhi Li, PhD

Wangzhi Li, PhD

Managing Director, Equity Research-Biotech

Michael J. Higgins

Michael J. Higgins

Managing Director, Senior Biopharmaceuticals Equity Research

Yield-Oriented Equities

Mickey M. Schleien, CFA

Mickey M. Schleien, CFA

Managing Director, Equity Research

Christopher Nolan, CFA

Christopher Nolan, CFA

Executive Vice President, Equity Research

Energy, Power & Infrastructure

Michael C. Schmitz, CFA

Michael C. Schmitz, CFA

Managing Director, Equity Research

Telecom, Media & Technology

Jon R. Hickman

Jon R. Hickman

Managing Director, Equity Research

Glenn G. Mattson, Jr.

Glenn G. Mattson, Jr.

Vice President, Equity Research